Later, Serra et al.[61] demonstrated treatment of BEZ235, a dual PI3K/mTOR inhibitor, in HER2+ BC cells also led to potent ERK activation, but primarily through upregulation of the RTKs, particularly ERBB signalling. Here, EGFR is linked to breast cancer.